Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The CooperCOO -1.14%86 Days Sales Outstanding is 68.19 as of Apr. 2026, which is 15% above its 10-year median of 59.25. GuruFocus rates COO with a GF Score™ of 86/100 and a GF Value™ of $102.06 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 810 Medical Devices & Instruments companies, The Cooper ranks worse than 54.2% on this metric.
The Cooper's average Accounts Receivable for the
three
months ended in Apr. 2026 was $808 Mil. The Cooper's Revenue for the
three
months ended in Apr. 2026 was $1,082 Mil.
Hence, The Cooper's Days Sales Outstanding for the
three
months ended in Apr. 2026 was 68.19.
The historical rank and industry rank for The Cooper's Days Sales Outstanding or its related term are showing as below:
COO'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 49.81 Med: 59.25 Max: 69.33
Current: 69.33
During the past 13 years, The Cooper's highest Days Sales Outstanding was 69.33. The lowest was 49.81. And the median was 59.25.
COO's Days Sales Outstanding is ranked worse than 54.2% of 810
companies
in the Medical Devices & Instruments industry
Industry Median: 65.25
vs COO: 69.33
The Cooper's Days Sales Outstanding
increased
from Apr. 2025 (68.16) to Apr. 2026 (68.19).
The Cooper (NAS:COO) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
The Cooper Days Sales Outstanding Related Terms
The Cooper Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for The Cooper's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COO vs BAX, SOLV, ALGN: Days Sales Outstanding Comparison
For the Medical Instruments & Supplies subindustry, The Cooper's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Cooper Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where The Cooper's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Cooper (COO) has a Days Sales Outstanding of 68.19 as of Apr. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on The Cooper and its competitors. This is 15% above median its historical median of 59.25. Over the past decade, The Cooper's Days Sales Outstanding has ranged from 49.81 to 69.33. According to the industry distribution chart, The Cooper ranks #439 out of 810 companies in the Medical Devices & Instruments industry, placing it in the top 54.2%.
Is The Cooper's Days Sales Outstanding too high?
The Cooper's current Days Sales Outstanding of 68.19 is 15% above median its 10-year median of 59.25. Over the past 10 years, this metric has ranged from a low of 49.81 to a high of 69.33. The Medical Devices & Instruments industry median Days Sales Outstanding is 65.25. The Cooper's value of 68.19 is 4.5% above this industry median. Based on the distribution chart, The Cooper ranks #439 out of 810 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, The Cooper has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Cooper's Days Sales Outstanding compare to BAX and SOLV?
According to the Medical Devices & Instruments industry distribution chart, The Cooper ranks #439 out of 810 companies for Days Sales Outstanding. This places The Cooper in the lower half of its industry. The industry median Days Sales Outstanding is 65.25. The Cooper's value of 68.19 is 4.5% above this benchmark. Historically, The Cooper's own Days Sales Outstanding has ranged from 49.81 to 69.33 over the past decade. While the company's 10-year median is 59.25 vs. the industry median of 65.25, The Cooper has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 65.25, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Cooper's current Days Sales Outstanding of 68.19 is 4.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on The Cooper and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 65.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Cooper's current Days Sales Outstanding is 68.19, which is 15% above median its own 10-year median of 59.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Cooper stock overvalued right now?
Based on GuruFocus' analysis, The Cooper (COO) is currently considered Significantly Undervalued. The stock's GF Value™ is $102.06, compared to a current price of $69.84 — trading 31.6% below its estimated fair value. The current Days Sales Outstanding is 68.19, which is 15% above median its 10-year median of 59.25 and 4.5% above the Medical Devices & Instruments industry median of 65.25. The Cooper's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For The Cooper (COO), the current Days Sales Outstanding is 68.19 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Cooper (COO) Overvalued in 2026?
Based on GuruFocus' analysis, The Cooper stock appears to be undervalued.
The current stock price of $69.84 is trading 31.6% below its estimated GF Value™ of $102.06.
GuruFocus considers The Cooper to be Significantly Undervalued.
Key valuation signals for COO:
Days Sales Outstanding: 68.19 (15% above median its 10-year median of 59.25)
GF Value™: $102.06 vs. price of $69.84 (31.6% below fair value)
Industry Position: 4.5% above the Medical Devices & Instruments median (#439 of 810)
No single metric tells the full story. See the COO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
86GF Score
Get the complete analysis for COO
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COO has been successfully added to your 
